Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 1447 drug-target rows in SSL view, for TSG = SMARCB1.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
docetaxel, thalidomide SMARCB1 BCL2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab SMARCB1 ABL1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab SMARCB1 BCL2 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) SMARCB1 ABL1 4
7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis SMARCB1 PDPK1 3
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine SMARCB1 TYMS 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCB1 ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCB1 EPHB4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCB1 PIK3CB 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCB1 SMO 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCB1 MAP2K1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCB1 FGFR3 3
amg 193, docetaxel, comparator amg 193 test tablet SMARCB1 BCL2 3
bms-986340, bms-936558-01, docetaxel SMARCB1 BCL2 3
capecitabine, cisplatin SMARCB1 TYMS 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus SMARCB1 MTOR 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan SMARCB1 FGFR3 3
gemcitabine SMARCB1 TYMS 3
pembrolizumab, belzutifan, lenvatinib SMARCB1 FGFR3 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab SMARCB1 TYMS 3
capecitabine SMARCB1 TYMS 6
everolimus SMARCB1 MTOR 6
nintedanib SMARCB1 FGFR3 6
regorafenib SMARCB1 ABL1 6
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin SMARCB1 TYMS 2
ab598, zimberelimab, fluorouracil, leucovorin, oxaliplatin SMARCB1 TYMS 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel SMARCB1 ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel SMARCB1 BCL2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel SMARCB1 TYMS 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel SMARCB1 MAP2K1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel SMARCB1 FGFR3 2
alendronate, etidronate, ibandronate, risedronate, raloxifene SMARCB1 ESR2 2
alvocidib, paclitaxel SMARCB1 BCL2 2
alvocidib, paclitaxel SMARCB1 CDK9 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan SMARCB1 BCL2 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan SMARCB1 TYMS 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine SMARCB1 TYMS 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 SMARCB1 TYMS 2
bbi-355, erlotinib, futibatinib SMARCB1 FGFR3 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SMARCB1 ABL1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SMARCB1 EPHB4 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SMARCB1 TYMS 2
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis SMARCB1 TYMS 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib SMARCB1 MAP2K1 2
biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging SMARCB1 TYMS 2
biospecimen collection, computed tomography, pemetrexed SMARCB1 TYMS 2
bryostatin 1, paclitaxel SMARCB1 BCL2 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin SMARCB1 BCL2 2
capecitabine, carboplatin, epirubicin hydrochloride SMARCB1 TYMS 2
capecitabine, docetaxel SMARCB1 BCL2 2
capecitabine, docetaxel SMARCB1 TYMS 2
capecitabine, irinotecan hydrochloride SMARCB1 TYMS 2
capecitabine, oxaliplatin SMARCB1 TYMS 2
capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy SMARCB1 TYMS 2
capecitabine, temozolomide SMARCB1 TYMS 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy SMARCB1 PDPK1 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy SMARCB1 BCL2 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection SMARCB1 BCL2 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu SMARCB1 BCL2 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy SMARCB1 BCL2 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy SMARCB1 TYMS 2
carboplatin, paclitaxel, panitumumab, radiotherapy SMARCB1 BCL2 2
carboplatin, paclitaxel, radiation therapy, telomerase-specific type 5 adenovirus obp-301 SMARCB1 BCL2 2
carboplatin, paclitaxel, three-dimensional conformal radiation therapy SMARCB1 BCL2 2
cetuximab, cisplatin, docetaxel, adjuvant therapy, neoadjuvant therapy SMARCB1 BCL2 2
cetuximab, cisplatin, fluorouracil, conventional surgery SMARCB1 TYMS 2
cft1946, trametinib, cetuximab SMARCB1 MAP2K1 2
chemotherapy, cisplatin, fluorouracil, low-let electron therapy, low-let photon therapy SMARCB1 TYMS 2
chemotherapy, cisplatin, paclitaxel, low-let electron therapy, low-let photon therapy SMARCB1 BCL2 2
cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy SMARCB1 BCL2 2
cisplatin, fluorouracil, conventional surgery, neoadjuvant therapy, radiation therapy SMARCB1 TYMS 2
cisplatin, fluorouracil, iressa, conventional surgery, radiation therapy SMARCB1 TYMS 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy SMARCB1 BCL2 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy SMARCB1 TYMS 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy SMARCB1 BCL2 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy SMARCB1 TYMS 2
cisplatin, fluorouracil, surgical procedure, radiation therapy SMARCB1 TYMS 2
cisplatin, paclitaxel, surgical procedure, radiation therapy SMARCB1 BCL2 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab SMARCB1 TYMS 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study SMARCB1 BCL2 2
cobimetinib, mehd7945a SMARCB1 MAP2K1 2
cpt- 11, cisplatin, celecoxib, radiation, surgery SMARCB1 PDPK1 2
dkn-01 150 mg, paclitaxel, pembrolizumab, dkn-01 300 mg SMARCB1 BCL2 2
docetaxel, 5-fu, radiotherapy, esophagectomy, dexamethasone SMARCB1 BCL2 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel SMARCB1 BCL2 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel SMARCB1 TYMS 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib SMARCB1 JAK2 2
erlotinib hydrochloride, oxaliplatin, fluorouracil, radiation therapy, conventional surgery, immunohistochemistry staining method, positron emission tomography, computed tomography, laboratory biomarker analysis, gene expression analysis, fludeoxyglucose f 18 SMARCB1 TYMS 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy SMARCB1 BCL2 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy SMARCB1 TYMS 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy SMARCB1 BCL2 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy SMARCB1 TYMS 2
fluorouracil, gemcitabine hydrochloride, leucovorin calcium SMARCB1 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, pharmacogenomic studies, pharmacological study SMARCB1 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study SMARCB1 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study SMARCB1 HDAC2 2
fluorouracil, oxaliplatin, conventional surgery, radiation therapy SMARCB1 TYMS 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a SMARCB1 FGFR3 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide SMARCB1 TYMS 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib SMARCB1 JAK2 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib SMARCB1 TYMS 2
irinotecan, capecitabine SMARCB1 TYMS 2
irinotecan, docetaxel SMARCB1 BCL2 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib SMARCB1 MAP2K1 2
laboratory biomarker analysis, oxaliplatin, pralatrexate SMARCB1 TYMS 2
lenvatinib, pembrolizumab SMARCB1 FGFR3 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate SMARCB1 FGFR3 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab SMARCB1 TYMS 2
m6620, cisplatin, capecitabine, radiotherapy SMARCB1 TYMS 2
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells SMARCB1 CACNG1 2
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells SMARCB1 CHRNA9 2
mirdametinib, bgb-3245 SMARCB1 MAP2K1 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed SMARCB1 BCL2 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed SMARCB1 TYMS 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a SMARCB1 BCL2 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a SMARCB1 TYMS 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a SMARCB1 FGFR3 2
nintedanib, pembrolizumab SMARCB1 FGFR3 2
ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine SMARCB1 BCL2 2
ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine SMARCB1 TYMS 2
olaparib SMARCB1 PARP3 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu SMARCB1 TYMS 2
onc-392, pembrolizumab, docetaxel SMARCB1 BCL2 2
oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, laboratory biomarker analysis SMARCB1 TYMS 2
pembrolizumab, guadecitabine, mocetinostat SMARCB1 HDAC2 2
pembrolizumab, lenvatinib SMARCB1 FGFR3 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu SMARCB1 TYMS 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu SMARCB1 FGFR3 2
pembrolizumab, paclitaxel, docetaxel, irinotecan SMARCB1 BCL2 2
pembrolizumab, sonidegib SMARCB1 SMO 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SMARCB1 BCL2 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SMARCB1 TYMS 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SMARCB1 FGFR3 2
pemetrexed, bevacizumab SMARCB1 TYMS 2
pharmacological study, romidepsin SMARCB1 HDAC2 2
pralatrexate, docetaxel, fludeoxyglucose f 18, positron emission tomography SMARCB1 BCL2 2
pralatrexate, docetaxel, fludeoxyglucose f 18, positron emission tomography SMARCB1 TYMS 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery SMARCB1 FGFR3 2
ramucirumab, paclitaxel SMARCB1 BCL2 2
regorafenib, laboratory biomarker analysis SMARCB1 ABL1 2
sar444881, pembrolizumab, cetuximab, carboplatin, pemetrexed SMARCB1 TYMS 2
selumetinib, medi4736, tremelimumab SMARCB1 MAP2K1 2
tislelizumab, pemetrexed SMARCB1 TYMS 2
whole brain low dose radiotherapy, pemetrexed, sintilimab, chemotherapy SMARCB1 TYMS 2
binimetinib SMARCB1 MAP2K1 6
bosutinib SMARCB1 ABL1 6
entrectinib SMARCB1 JAK2 6
erdafitinib SMARCB1 FGFR3 6
pazopanib SMARCB1 FGFR3 6
pemigatinib SMARCB1 FGFR3 6
ponatinib SMARCB1 ABL1 6
romidepsin SMARCB1 HDAC2 6
tadalafil SMARCB1 PDE5A 6
18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography SMARCB1 PARP3 1
3-dimensional conformal radiation therapy, biospecimen collection, capecitabine, chemotherapy, computed tomography, erlotinib hydrochloride, fluorouracil, gemcitabine hydrochloride, intensity-modulated radiation therapy, magnetic resonance imaging, quality-of-life assessment, x-ray imaging SMARCB1 TYMS 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat SMARCB1 HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat SMARCB1 HDAC2 1
4-dimensional computed tomography, fluorouracil, gemcitabine hydrochloride, laboratory biomarker analysis, leucovorin calcium, nelfinavir mesylate, oregovomab, stereotactic body radiation therapy, therapeutic conventional surgery SMARCB1 TYMS 1
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) SMARCB1 BCL2 1
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) SMARCB1 MAP2K1 1
5-fluorouracil, docetaxel, oxaliplatin SMARCB1 BCL2 1
5-fluorouracil, leucovorin, oxaliplatin, docetaxel, carboplatin, paclitaxel, neoadjuvant radiation SMARCB1 BCL2 1
5-fluoruracil, cisplatinum, docetaxel SMARCB1 BCL2 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy SMARCB1 BCL2 1
6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, laboratory biomarker analysis SMARCB1 TYMS 1
7-hydroxystaurosporine, fluorouracil SMARCB1 PDPK1 1
7-hydroxystaurosporine, fluorouracil SMARCB1 TYMS 1
7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis SMARCB1 PDPK1 1
9-ing-41, retifanlimab, gemcitabine, abraxane SMARCB1 TYMS 1
abbv-400, budigalimab, fluorouracil, leucovorin, oxaliplatin SMARCB1 TYMS 1
abemaciclib, ly3023414, gemcitabine, capecitabine SMARCB1 TYMS 1
abraxane (nab-paclitaxel), gemcitabine SMARCB1 TYMS 1
adct-601, gemcitabine SMARCB1 TYMS 1
adebrelimab, apatinib, tegafur SMARCB1 TYMS 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy SMARCB1 HDAC2 1
aee788, everolimus SMARCB1 MTOR 1
afatinib dimaleate, capecitabine, laboratory biomarker analysis SMARCB1 TYMS 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SMARCB1 PARP3 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SMARCB1 ABL1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SMARCB1 EPHB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SMARCB1 MTOR 1
afatinib, docetaxel, radiation therapy SMARCB1 BCL2 1
afuresertib, nab paclitaxel, docetaxel, sintilimab SMARCB1 BCL2 1
ag-013736, gemcitabine, gemcitabine, placebo SMARCB1 TYMS 1
agen1423, botensilimab, gemcitabine, nab-paclitaxel SMARCB1 TYMS 1
agent-797, botensilimab, balstilimab, ramucirumab, paclitaxel SMARCB1 BCL2 1
ags-1c4d4, gemcitabine SMARCB1 TYMS 1
ak104, ak104, gemcitabine, nab-paclitaxel SMARCB1 TYMS 1
ak104, oxaliplatin, capecitabine SMARCB1 TYMS 1
ak109, paclitaxel, paclitaxel, ak104 SMARCB1 BCL2 1
ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine SMARCB1 TYMS 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib SMARCB1 TYMS 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib SMARCB1 MAP2K1 1
albumin-bound paclitaxel (abi-007), gemcitabine SMARCB1 TYMS 1
aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim SMARCB1 IL2RB 1
aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim SMARCB1 TYMS 1
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation SMARCB1 IL2RB 1
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation SMARCB1 BCL2 1
aldesleukin, autologous tumor cell vaccine, muromonab-cd3, sargramostim, therapeutic autologous lymphocytes, surgical procedure, radiation therapy SMARCB1 IL2RB 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes SMARCB1 IL2RB 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.